Quince Therapeutics Inc (QNCX) - News Archive

Empowering Therapeutics: Quince Therapeutics’ Advanced PK Modeling Study for Ataxia-Telangiectasia Treatment In a promising stride towards developing biologically attuned therapies for rare diseases, Quince Therapeutics...

Unlocking Potential: Quince Therapeutics Fiscal Year 2024 Financial Results and Strategic Developments in Rare Disease Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a pioneering biotechnology enterprise headqua...

In a significant advancement for the field of pediatric neurology and rare disease therapeutics, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology firm based in South San Francisco, has presented safe...

Quince Therapeutics Unveils Promising Data on EryDex Treatment for Ataxia-Telangiectasia and Reports Encouraging Financial Outlook In the realm of biotechnology, the quest for effective treatments for rare diseases rema...

South San Francisco, Calif. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its innovative EryDex...

Quince Therapeutics, a distinguished player in the biotechnology industry, is persistently pushing the boundaries of innovation with its unique patient-driven drug delivery technology. Its unwavering dedication to revol...